Publications by authors named "Maho Nakazawa"

Article Synopsis
  • * The study analyzed fecal microbiota, organic acids, and inflammatory markers in 11 dogs with CE and SCL, alongside 16 healthy controls, using advanced analysis techniques for deeper insights.
  • * Results showed lower levels of beneficial bacteria and higher levels of harmful bacteria in diseased dogs, along with abnormalities in succinic acid metabolism, suggesting potential links to canine inflammatory bowel disease and the possibility for microbiome-targeted treatments.
View Article and Find Full Text PDF
Article Synopsis
  • Interstitial lung disease is a frequent complication in anti-synthetase syndrome (ASS), marked by lymphocyte infiltration in the lungs.
  • The study reports that B cells from lung lesions in ASS patients produce disease-specific autoantibodies, with varying percentages based on the type of antibody present.
  • Autoantibody production was also unexpectedly found in salivary glands of ASS patients, suggesting that this tissue involvement may reflect a broader autoimmune response and offers insights into how organ manifestations in autoimmune diseases occur.
View Article and Find Full Text PDF

Anaphylaxis is a severe life-threatening hypersensitivity reaction induced by mast cell degranulation. Among the various mediators of mast cells, little is known about the role of tryptase. Therefore, we aimed to elucidate the role of protease-activating receptor-2 (PAR-2), a receptor activated by tryptase, in murine anaphylactic models using PAR-2-deficient mice and newly generated tryptase-deficient mice.

View Article and Find Full Text PDF

Epidermal growth factor receptors 1 and 2 (EGFR and HER2) are frequently overexpressed in various malignancies. Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2. Although a phase III trial failed to show the survival benefits of lapatinib treatment after first-line chemotherapy in patients with EGFR/HER2-positive metastatic urothelial carcinoma, the efficacy of lapatinib for untreated urothelial carcinoma is not well defined.

View Article and Find Full Text PDF
Article Synopsis
  • Interstitial lung disease (ILD) can be a serious complication of autoimmune diseases like rheumatoid arthritis, Sjögren's syndrome, and mixed connective tissue disease, but little is known about how the immune system responds in the lungs.
  • Researchers examined bronchoalveolar fluid (BALF) and serum from 15 patients, finding higher levels of disease-related autoantibodies in BALF, which hints that these antibodies might be produced in the lungs rather than just in the bloodstream.
  • They identified specific autoantibodies related to these diseases, and noted complex changes in these antibodies, suggesting that the lungs are an active site of autoimmunity in patients with ILD linked to autoimmune diseases.
View Article and Find Full Text PDF

Nasal lymphoma (NL) is the most common nasal tumor in cats, and radiotherapy, chemotherapy, or a combination of these treatments have been described as the treatment for this disease. However, the previous studies included various machines and protocols of radiotherapy. Therefore, we aimed to retrospectively compare the prognosis among cases treated with palliative hypofractionated radiotherapy, chemotherapy, and a combination of them with united machine and protocol of radiotherapy.

View Article and Find Full Text PDF

Objective: To identify immunologic factors in the lungs of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with idiopathic inflammatory myopathy-associated ILD (IIM-ILD) and to examine their pathologic mechanisms.

Methods: Eleven patients with RA-ILD, 16 with IIM-ILD, 6 with drug-induced ILD (DI-ILD), and 8 healthy controls were enrolled. Peripheral blood (PB) and bronchoalveolar lavage (BAL) fluid were immunophenotyped by flow cytometry.

View Article and Find Full Text PDF

Regulatory T cells (Tregs) can be targeted in cancer immunotherapy. A previous study has shown that the chemokine CCL17 and the receptor CCR4 play a role in Treg recruitment in canine urothelial carcinoma. Here, we describe the association of tumor-infiltrating Tregs with CCL17/CCR4 expression in dogs with other carcinomas.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD) is a common gastrointestinal disease in dogs. Decreased production of intestinal immunoglobulin A (IgA) has been suggested as a possible pathogenesis in a subset of canine IBD; however, the underlying cause remains unclear. Sphingosine-1-phosphate (S1P) is a lipid mediator that regulates intestinal IgA production by controlling lymphocyte trafficking in mice.

View Article and Find Full Text PDF

Objective: To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD).

Methods: We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse.

View Article and Find Full Text PDF

Background: In granulomatosis with polyangiitis (GPA), peripheral nerve involvement is common but central nervous system (CNS) involvement is extremely rare and treatment strategy has not been established. We report a case of intravenous cyclophosphamide (IVCY)-resistant GPA with associated cranial neuropathies that was successfully treated with rituximab (RTX).

Case Presentation: A 37-year-old man with intractable sinusitis had several months of headache, hoarseness, and dysphagia; a month of right-sided deafness and nasal bleeding; and a week of dysarthria, steppage gait, and numbness in the right L5 distribution.

View Article and Find Full Text PDF

To identify risk factors for the recurrence of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM). Forty-four PM/DM-ILD patients who had been treated with glucocorticoid and/or immunosuppressive agents as a remission induction therapy were enrolled. The patients were first classified into two groups: the early recurrence group that recurred within 52 weeks, and the non-early recurrence group, which was further classified into the late recurrence group that recurred after 52 weeks, and the non-recurrence group.

View Article and Find Full Text PDF